The interference of monoclonal antibodies with laboratory diagnosis: clinical and diagnostic implications

References

• Afif W, Loftus EV, Faubion WA. (2010). Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol, 105, 1133–9
   PubMed Web of Science ®Google Scholar
• Alshekaili J, Li C, Cook MC. (2010). Heterophile interference accounts for method-specific ds-DNA antibodies in patients receiving anti-TNF treatment. Rheumatology, 49, 891–7
   PubMed Web of Science ®Google Scholar
• Baxter Health Care. (2011). Gammagard Prescribing Information Section 5.10 Interference with Laboratory Tests. Westlake Village, California, USA. Available from: www.baxter.com/healthcare_professionals [last accessed 4 Oct 2013]
   Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol, 10, 345–52
   PubMed Web of Science ®Google Scholar
• Berth M, Delanghe J. (2004). Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg, 59, 263–73
   PubMed Web of Science ®Google Scholar
• Boerman OC, Segers MFG, Poels LG, et al. (1990). Heterophile antibodies in human sera causing falsely increased results in Ca 125 immunofluorometric assay. Clin Chem, 36, 888–91
   PubMed Web of Science ®Google Scholar
• Book BK, Agarwal A, Milgrom AB, et al. (2005). New cross match technique eliminates interference by humanized and chimeric MABs. Transplant Proc, 37, 640–2
   PubMed Web of Science ®Google Scholar
• Boswell CA, Brechbiel M. (2009). Development of radioimmunotherapeutic and diagnostic antibodies. SSNM 2009 Mid Winter Symposium After Bench to Bedside: Impact on Clinical Outcome. Available from: http://apps.snm.org/docs/CME/PresenterItems/EventID_79/PresenterItemTypeID [last accessed 4 Oct 2013]
   Google Scholar
• Burch J, Onysko M. (2012). Current standards and future treatments of rheumatoid arthritis. Formulary J Modern Med Network, 1–8. Available from: www.mednetmedical.com [last accessed 4 Oct 2013]
   Google Scholar
• Cambrosio A, Keating P. (1992). Between fact and technique: The beginnings of hybridoma technology. J Hist Biol, 25, 175–230
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Coney L, et al. (2009). Preclinical development of monoclonal antibodies. mAbs, 5, 505–16
   Google Scholar
• Despres N, Grant AM. (1998). Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem, 44, 440–54
   PubMed Web of Science ®Google Scholar
• Dimeski G. (2008). Interference testing. Clin Biochem Rev, 29, I S43–8
   Google Scholar
• Emerson JF, Lai KKY. (2013). Endogenous antibody interferences in immunoassays. Lab Med, 44, 69–73
   Google Scholar
• Hamilton RG. (2006). Accuracy of US FDA cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol, 117, 759–66
   PubMed Web of Science ®Google Scholar
• Ismail AA. (2009). Interference from endogenous antibodies in automated immunoassays: what laboratorians need to know. J Clin Pathol, 62, 673–8
   PubMed Web of Science ®Google Scholar
• Janssen Biotech. (2013). Remicade Package Insert. Available from: www.remicade.com/about-janssen-biotech [last accessed 4 Oct 2013]
   Google Scholar
• Kricka LJ. (1999). Human anti-animal antibody interferences in immunological assays. Clin Chem, 45, 942–56
   PubMed Web of Science ®Google Scholar
• LeFranc MP, Ehrenmann F, et al. (2012). IMGT the international imMugenetics information system. Methods Mol Biol 907:3–37
   Google Scholar
• Levin O, Morris LF, Wah DT, et al. (2011). Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocrine Pract, 17, e8–11
   PubMed Web of Science ®Google Scholar
• Lichtiger B, Rogge K. (1991). Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med, 115, 467–9
   PubMed Web of Science ®Google Scholar
• Lichtiger B. (1994). Laboratory serologic problems associated with administration of intravenous IgG. Transfusion Medicine, 3(2), 1995 April–June. Available from: www.mdanderson.org/publications/current-issues-in-transfusion-medicine/issues/1994-april-june.html [last accessed 4 Oct 2013]
   Google Scholar
• Marks V. (2002). False-positive immunoassay results: A multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem, 48, 2008–16
   PubMed Web of Science ®Google Scholar
• McCudden CR, Voorhees PM, Hainsworth SA, et al. (2010). Interference of MAB Therapies with serum Protein Electrophoresis Tests. Clin Chem, 56, 1897–904
   PubMed Web of Science ®Google Scholar
• Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. (2011). Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest, 40(3), 299–338
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle, RA, Buadi FK. (2010). Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc, 85, 945–8
   PubMed Web of Science ®Google Scholar
• Roberts WL, Fontenot JD, Lehman CM. (2000). Overestimation of hemoglobin in a patient with an IgA-kappa monoclonal gammopathy. Arch Pathol Lab Med, 124, 616–8
   PubMed Web of Science ®Google Scholar
• Roy V. (2009). Artifactual Laboratory abnormalities in patients with paraproteins. South Med J, 102, 167–70
   PubMed Web of Science ®Google Scholar
• Rozin AP. (2004). Matters arising: Infliximab efficiency and failure. Ann Rheum Dis, 63, 751–2
   PubMed Web of Science ®Google Scholar
• Seghers J, Schrurs F, De Nayer P, Beckers C. (1989). Interference in thyrotropin (TSH) determination: falsely elevated TSH values in a transplanted patient. Eur J Nucl Med, 15, 194–6
   PubMedGoogle Scholar
• Siddiqui MZ. (2010). Monoclonal Antibodies as Diagnostics; an Appraisal. Indian J Pharm Sci, 72, 12–17
   PubMed Web of Science ®Google Scholar
• Sosolik RC, Hitchcock CL, Becker WJ. (1997). Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Am J Clin Pathol, 107, 506–10
   PubMed Web of Science ®Google Scholar
• Stern M, Herrmann R. (2005). Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol, 54, 11–29
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Viljoen A. (2011). Analytic error and interference in immunoassay: minimizing risk. Ann Clin Biochem, 48, 418–32
   PubMed Web of Science ®Google Scholar
• Tate J, Ward G. (2004). Interferences in immunoassay. Clin Biochem Rev, 25, 105–20
   PubMedGoogle Scholar
• U.S. Department of Health and Social Services. (1997). Review criteria for assessment of rheumatoid factor in vitro diagnostic devices using EIA, ELISA, particle agglutination tests, and laser and rate nephelometry. Washington, DC: US Dept. Health and Social Services
   Google Scholar
• Van Dongen GAMS, Visser GWM, Lub-de Hooge MN, et al. (2007). Immuno-PET: A navigator in MAB development and applications. Oncologist, 12, 1379–89
   PubMed Web of Science ®Google Scholar
• Van Kroonenburgh MJPG, Pauwels EKJ. (1988). Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun, 9, 919–30
   PubMed Web of Science ®Google Scholar
• Wagenknecht D, Sizemore J, House K, et al. (2004). Humanized monoclonal Campath-H1 can mimic alloantibodies in CDC and flow cytometry crossmatches. Human Immunol, 65, S1, 73
   Web of Science ®Google Scholar
• Yang Y, Howanitz PJ, Howanitz JH, et al. (2008). Paraproteins are a common cause of interferences with automated chemistry methods. Arch Pathol Lab Med, 132, 217–23
   PubMed Web of Science ®Google Scholar